Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBERON: Tozorakimab in COPD with history of exacerbations
jRCT2031210563Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of tozorakimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualized rate of moderate to severe COPD exacerbations in former smokers. Started Jan 2022; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031210563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210563.